Best Metabolic Diseases Companies in Massachusetts, United States
The 38 best Metabolic Diseases companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nimbus Therapeutics.
Ranked: Best Metabolic Diseases companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Nimbus Therapeutics Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 36 mo ago | 81 81 → 99 (+22%) | Jeb Keiper CEO | WordPressApple iCloud MailMySQL+14 | — | — |
| 2 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 11 mo ago | — | Ron Renaud Founder & CEO | DrupalApple iCloud MailPHP+27 | — | 1 internship |
| 3 | Fractyl Provider of Endoscopic procedure for type - 2 diabetes | $345M | 62 mo ago | 79 79 → 106 (+34%) | Jay Caplan Co-founder and President | WordPressApple iCloud MailMicrosoft 365+28 | — | — |
| 4 | Gelesis Satiety induction through hydrogel capsules | $182M | 81 mo ago | 93 | Yishai Zohar Founder & CEO | PleskPHPVimeo+15 | 173 patents Therapeutic hydrogels for gut microbiome modulation and obesity/constipation treatment | — |
| 5 | Kaleido Biosciences Developer of microbiome metabolic therapies for inflammatory conditions | $165M | 98 mo ago | 81 | — | — | 166 patents Therapeutic glycans and oligosaccharide drug formulation technologies | — |
| 6 | Allurion Developer of Gastric Balloon device for weight loss management 50Funding top 22%Customers top 23%Product top 24%Tech top 26% All 13 signals ▾Fundingtop 22% Customerstop 23% Producttop 24% Techtop 26% Moattop 38% Markettop 40% Innovationtop 50% Talentbottom 49% Patentsbottom 42% Globalbottom 42% Newsbottom 36% Fin. healthbottom 35% Growthbottom 29% Funding: Raised $151M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Customers: Play-Store rating 4.75★ across 1,421 ratings (1 apps) · Review volume +53% in 6 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $151M | 10 mo ago | 252 | Samuel Levy Founder | DrupalApple iCloud MailPHP+31 | 38 patents Temporary intragastric weight‑loss balloons and deployment devices. | 1 award |
| 7 | Judo Bio Developer of therapeutics for systemic and renal diseases | $150M | 23 mo ago | — | Rajiv Patni CEO | WordPressMySQLPHP+15 | — | — |
| 8 | Keryx Biopharmaceuticals Markets ferric citrate for the treatment chronic kidney disease. | $146M | 131 mo ago | 142 | — | — | 112 patents Oral ferric citrate formulations for iron supplementation in chronic kidney disease patients. | — |
| 9 | Axial Therapeutics Developer of small molecule therapeutics for central nervous system disorder | $110M | 19 mo ago | 12 12 → 12 (+0%) | A Campbell CEO | — | — | — |
| 10 | Sigilon Developer of therapeutics to treat chronic diseases | $104M | 77 mo ago | 66 | Omid Veiseh Co-Founder | — | — | — |
| 11 | Regor Provider of therapeutics related to oncology, autoimmune and metabolic disease | $90M | 66 mo ago | 36 | — | — | — | — |
| 12 | Synta Pharmaceuticals Small molecule drugs for cancer and chronic inflammatory conditions | $90M | 185 mo ago | 37 | — | — | 1,214 patents HSP90 inhibitor combination therapies for ovarian and other cancers | — |
| 13 | Axcella Developer of targeted therapeutics for infectious and metabolic disorders | $87M | 110 mo ago | 11 | — | — | — | — |
| 14 | DermBiont Developer of microbial therapeutics designed to treat skin diseases | $73M | 35 mo ago | 36 | Nichola Eliovits Co-Founder | Squarespace CommerceSquarespaceTypeScript+16 | 49 patents Topical pharmaceutical formulations delivering PK/AKT inhibitors for skin disease therapy. | — |
| 15 | Alnara Pharmaceuticals Speciality company that develops protein therapeutics for treatment of metabolic diseases | $55M | 199 mo ago | 10 | Christoph Westphal Co-Founder | — | — | — |
| 16 | i2o Therapeutics Provider of an oral drug delivery solution | $54M | 34 mo ago | 6 | Samir Mitragotri Co-Founder | — | — | — |
| 17 | Walden Developer of drugs for the treatment of chronic kidney diseases | $51M | 71 mo ago | 26 | Blaine Mckee President and Chief Executive Officer | — | — | — |
| 18 | Alinea Pharmaceuticals Developing therapeutics for the treatment of diabetes & other metabolic disorders. | $45M | 250 mo ago | — | Robert Mashal CEO & President | — | — | — |
| 19 | Courtagen Provider of solutions for neurological & metabolic disorders | $41M | 135 mo ago | 128 | — | — | — | — |
| 20 | AOBiome Therapeutics company restoring immune functionality to treat inflammatory skin conditions | $34M | 116 mo ago | 8 | David Whitlock Co-Founder | WordPressMySQLPHP+17 | 264 patents Microbiome-based ammonia‑oxidizing bacterial therapeutics for skin, nasal, ocular, auditory, and urogenital health | — |
| 21 | Sentien Biotechnologies Developer of stem cell based device product for acute organ failure | $13M | 113 mo ago | 7 | Biju Parekkadan Co-Founder | — | — | — |
| 22 | Rediscovery Life Sciences Developing drugs for treating acute kidney injury | $9M | 41 mo ago | 4 | — | — | — | — |
| 23 | Xeno Biosciences Developer of transformational therapies for metabolic diseases | $8M | 44 mo ago | 5 | — | — | — | — |
| 24 | Anagram Developer of therapeutics for metabolic diseases | $8M | 4 mo ago | 20 | Robert Gallotto President and Chief Executive Officer | — | — | — |
| 25 | Hero Patch Developer of antibodies or small molecules for drug delivery | $8M | 39 mo ago | 14 | Hojat Rezaei Co-Founder & CTO | — | — | — |
| 26 | Cortria Corporation Developer of drugs for cardiovascular and metabolic disease | $2M | 206 mo ago | — | Daniel Grau CEO | — | 31 patents Patents concentrated in health & consumer products | — |
| 27 | Nivarta Early stage drug development company for diabetes and obesity | $1M | 167 mo ago | — | Murali Vemula Founder | — | — | — |
| 28 | Artus Therapeutics Developer of therapeutics for immunological disorders | $501K | 62 mo ago | 3 | Venkatakrishna Jala Co-Founder | — | — | — |
| 29 | Energesis Pharmaceuticals Developer of drugs to treat obesity, diabetes, and related metabolic diseases | $419K | 135 mo ago | — | Brian Freeman President & CEO | — | — | — |
Top 12 Metabolic Diseases companies in Massachusetts
#1
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
- Oct 2025Series B$600M
- Oct 2024Series A$400M
#2
Public · Wellesley, Massachusetts · founded 2009 · 252 employees$150.5Mraised▾
Developer of Gastric Balloon device for weight loss management. The Program targets obesity by combining a gastric balloon that occupies stomach space to promote fullness with behavioral coaching and an app for tracking progress.
- Nov 2025Post IPO$5M
- Jan 2025Post IPO$2.5M
- Apr 2024Post IPO$48M
- Dec 2023Post IPO$122.5K
#3
Series B · Natick, Massachusetts · founded 2017 · 20 employees$8.2Mraised▾
Developer of therapeutics for metabolic diseases. It offers orally-delivered enzymes as therapies for malabsorption syndrome and nutrient metabolism disorders which is s caused by enzyme deficiencies or genetic mutations.
- May 2026Series B$250M
- Aug 2022Grant (prize money)$1.8M
- Jan 2018Grant (prize money)$3M
- Aug 2017Series A$8.2M
#4
Series D · Waltham, Massachusetts · founded 2016 · 12 employees$110.3Mraised▾
Developer of small molecule therapeutics for central nervous system disorder. The company's flagship candidate AB-2004 is for the gut-brain axis treatment paradigm for neurodegenerative diseases like autism and Parkinson's disease. It is an oral-based product and stays in the GI tract and removes certain metabolites for the treatment of neurology diseases.
- Jan 2025Series D$19.4M
- Oct 2023Series C$11.1M
- Oct 2021Series C$37.2M
- Jul 2020Grant (prize money)$440K
#5
Series A · Cambridge, Massachusetts · founded 2021$150Mraised▾
Developer of therapeutics for systemic and renal diseases. It offers oligonucleotide medicines that enable receptor-mediated uptake of oligonucleotides to specific kidney cell types using proprietary ligand-siRNA conjugate that results in gene silencing of disease-modifying target genes.
- Oct 2024Series A$100M
- Jul 2024Series A$25M
- May 2024Series A$5M
- Nov 2022Series A$20M
#6
Series F · Cambridge, Massachusetts · founded 2009 · 81 employees$637Mraised▾
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
- Sep 2023Series F$210M
- Sep 2022Series E$125M
- Jul 2021Series D$105M
- Oct 2020Series C$60M
#7
Series B · Melrose, Massachusetts · founded 2015 · 36 employees$73.3Mraised▾
Developer of microbial therapeutics designed to treat skin diseases. The topical therapeutic candidates include DBI-001 for eczema, athlete's foot, and nail fungus, DBI-002 for inflammatory dandruff, and SM-020 for benign skin tumors.
- Oct 2023Series B$32.7M
- Mar 2023Conventional Debt$4.7M
- Sep 2022Conventional Debt$2.5M
- Dec 2021Series A$28M
#8
Public · Lexington, Massachusetts · founded 2010 · 79 employees$345.3Mraised▾
Provider of Endoscopic procedure for type - 2 diabetes. Fractyl is developing an investigational, device-based, minimally invasive, trans-oral procedure known as Revita duodenal mucosal resurfacing (DMR) that aims to improve the body's response to sugar. Performed using Fractyl’s proprietary Revita System, the DMR procedure uses hydrothermal ablation to modify the lining of the duodenum. Fractyl’s proprietary Revita™ System consists of a console and a novel single-use balloon catheter. The physician first introduces the Revita™ catheter through the mouth into the small intestine using a standard endoscope to visualize the catheter position. The physician then uses the Revita™ System to activate a precisely controlled heated balloon at the end of the catheter to treat the lining of the duodenum. The lining of the duodenum contains cells that affect glucose control and insulin resistance.
- Jun 2021Series F$100M
- Aug 2020Series E$55M
- Mar 2020Series D$44.8M
- Nov 2017Series D$44M
#9
Series A · Boston, Massachusetts · founded 2019 · 6 employees$53.5Mraised▾
i2o is a provider of an oral drug delivery solution. It is a liquid technology, this platform protects the drug cargo while also enhances permeation across the epithelial lining when administered orally.
- Oct 2023Series A$3.5M
- Aug 2023Series A$46M
- Dec 2020Seed—
- Dec 2020Conventional Debt$600K
#10
Public · Boston, Massachusetts · founded 2006 · 93 employees$182.5Mraised▾
Gelesis develops technologies for the treatment of obesity and other unmet medical needs. It offers Attiva, a superabsorbent hydrogel composed entirely from food components, is administered in the form of small particles that are designed to swell after ingestion with water, and occupy the gastric and intestinal cavities, inducing a feeling of satiety that lasts beyond its transit time in the stomach.
- Dec 2019Conventional Debt$8.3M
- Dec 2019Grant (prize money)$12.9M
- Dec 2019Series D$63.4M
- Apr 2019Grant (prize money)$10.6M
#11
Deadpooled · Cambridge, Massachusetts · founded 2015 · 81 employees$165Mraised▾
Developer of microbiome metabolic therapies for inflammatory conditions. The company is developing therapeutic products to modulate the human microbiome for the treatment of human diseases associated with microbial imbalance.
- Jun 2018Series C$101M
- Jun 2017Series B—
- Series A—
#12
Acquired · Boston, Massachusetts · founded 2018 · 36 employees$90Mraised▾
Provider of therapeutics related to oncology, autoimmune and metabolic disease. It builds a multi-disciplinary computational platform from structure biology, biopharmaceutics, PK/PD modeling to bioinformatics proactively to stimulate drug discovery from target identification, lead optimization, to clinical Proof of concept.
- Feb 2021Series B$90M
- 2018Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Metabolic Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Massachusetts is moving
A read on the academic research around Biotechnology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 169 papers.
- Massachusetts General Hospital62
- Massachusetts Institute of Technology58
- University of Massachusetts Chan Medical School20
- University of Massachusetts Amherst18
- University of Massachusetts Boston7
- Messenger RNA1→3
- Transcription (linguistics)3→4
- In vivo10
- Biodistribution3
- Cancer research2
- Apoptosis2
- Sustainability2
- Food industry3
- Biochemical engineering3
- Glioma2
- Food science2
- Synthetic biology2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.